Abstract| Volume 87, ISSUE 9, SUPPLEMENT , S148-S149, May 01, 2020

Cariprazine Alleviates Core Behavioral Deficits in the Prenatal Valproic Acid Exposure Rat Model of Autism Spectrum Disorder

      Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by socio-communicational deficits and restricted/repetitive behaviors. There is no approved pharmacotherapy for the treatment of these core symptoms. Cariprazine is an oral dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist. This study investigated the effects of cariprazine in a preclinical ASD model.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect